1.44
-0.08(-5.26%)
Currency In USD
| Previous Close | 1.52 |
| Open | 1.52 |
| Day High | 1.53 |
| Day Low | 1.44 |
| 52-Week High | 2.08 |
| 52-Week Low | 0.28 |
| Volume | 1.56M |
| Average Volume | 2.46M |
| Market Cap | 523.29M |
| PE | -4.5 |
| EPS | -0.32 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 0.86 |
| Change | -0.08 |
If you invested $1000 in Lexicon Pharmaceuticals, Inc. (LXRX) 10 years ago, it would be worth $131.03 as of October 22, 2025 at a share price of $1.44. Whereas If you bought $1000 worth of Lexicon Pharmaceuticals, Inc. (LXRX) shares 5 years ago, it would be worth $1,058.82 as of October 22, 2025 at a share price of $1.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
GlobeNewswire Inc.
Oct 08, 2025 11:59 AM GMT
Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN ActTHE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterd
Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
GlobeNewswire Inc.
Sep 22, 2025 8:00 PM GMT
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA fee